Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations - PubMed

Androgen receptor expression in estrogen receptor-negative breast cancer. Immunohistochemical, clinical, and prognostic associations

S Nicholas Agoff et al. Am J Clin Pathol. 2003 Nov.

Abstract

We sought to determine the prevalence of androgen receptor (AR) expression in a predominantly estrogen receptor (ER)-negative subset of breast cancers and delineate the immunohistochemical and clinical associations, including whether AR expression has prognostic significance in ER-negative tumors. We identified 69 ER-negative and 19 ER-positive breast cancer cases with concurrent immunohistochemical prognostic panels (ER, PR, HER-2/neu, Ki-67, and p53); immunohistochemical analysis was performed for AR using standard techniques. Clinical data were extracted from medical records. chi 2 tests were used to assess associations between variables. AR was found in 49% (34/69) of ER-negative and 89% (17/19) of ER-positive cases. In ER-negative tumors, AR was associated with increased age (P = .02), postmenopausal status (P < .001), tumor grade (P = .03), tumor size (P = .03), and HER-2/neu overexpression (P = .003). In ER-positive tumors, AR was associated with progesterone receptor expression (P < .03). In univariate analysis of ER-negative tumors, patients with AR-positive tumors had significantly better disease-free survival (P = .049). AR is expressed in a significant number of ER-negative cases and shows significant associations with important clinical and pathologic prognostic factors.

Similar articles

• Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers.

  Castellano I, Allia E, Accortanzo V, Vandone AM, Chiusa L, Arisio R, Durando A, Donadio M, Bussolati G, Coates AS, Viale G, Sapino A. Castellano I, et al. Breast Cancer Res Treat. 2010 Dec;124(3):607-17. doi: 10.1007/s10549-010-0761-y. Epub 2010 Feb 3. Breast Cancer Res Treat. 2010. PMID: 20127405

• Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies.

  Moinfar F, Okcu M, Tsybrovskyy O, Regitnig P, Lax SF, Weybora W, Ratschek M, Tavassoli FA, Denk H. Moinfar F, et al. Cancer. 2003 Aug 15;98(4):703-11. doi: 10.1002/cncr.11532. Cancer. 2003. PMID: 12910513

• Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.

  Arpino G, Weiss H, Lee AV, Schiff R, De Placido S, Osborne CK, Elledge RM. Arpino G, et al. J Natl Cancer Inst. 2005 Sep 7;97(17):1254-61. doi: 10.1093/jnci/dji249. J Natl Cancer Inst. 2005. PMID: 16145046

• Androgen receptor as a target for the treatment of hormone receptor-negative breast cancer: an unchartered territory.

  Nahleh Z. Nahleh Z. Future Oncol. 2008 Feb;4(1):15-21. doi: 10.2217/14796694.4.1.15. Future Oncol. 2008. PMID: 18240997 Review.

• Action and counter-action of hormones in human ovarian cancer.

  Roa BR, Slotman BJ. Roa BR, et al. Anticancer Res. 1989 Jul-Aug;9(4):1005-7. Anticancer Res. 1989. PMID: 2683984 Review.

Cited by

• Targeting the androgen receptor in prostate and breast cancer: several new agents in development.

  Proverbs-Singh T, Feldman JL, Morris MJ, Autio KA, Traina TA. Proverbs-Singh T, et al. Endocr Relat Cancer. 2015 Jun;22(3):R87-R106. doi: 10.1530/ERC-14-0543. Epub 2015 Feb 26. Endocr Relat Cancer. 2015. PMID: 25722318 Free PMC article. Review.

• Influence of Androgen Receptor Expression on the Survival Outcomes in Breast Cancer: A Meta-Analysis.

  Kim Y, Jae E, Yoon M. Kim Y, et al. J Breast Cancer. 2015 Jun;18(2):134-42. doi: 10.4048/jbc.2015.18.2.134. Epub 2015 Jun 26. J Breast Cancer. 2015. PMID: 26155289 Free PMC article.

• Lin28A activates androgen receptor via regulation of c-myc and promotes malignancy of ER-/Her2+ breast cancer.

  Shen H, Zhao L, Feng X, Xu C, Li C, Niu Y. Shen H, et al. Oncotarget. 2016 Sep 13;7(37):60407-60418. doi: 10.18632/oncotarget.11004. Oncotarget. 2016. PMID: 27494865 Free PMC article.

• Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells--identification of a novel androgen response element.

  Lanzino M, Sisci D, Morelli C, Garofalo C, Catalano S, Casaburi I, Capparelli C, Giordano C, Giordano F, Maggiolini M, Andò S. Lanzino M, et al. Nucleic Acids Res. 2010 Sep;38(16):5351-65. doi: 10.1093/nar/gkq278. Epub 2010 Apr 26. Nucleic Acids Res. 2010. PMID: 20421209 Free PMC article.

• Impact of Androgen Receptor Expression and the AR:ER Ratio on the Survival Outcomes in the Diverse Subgroups of Vietnamese Breast Cancer: A Single Institutional Retrospective Cohort Analysis.

  Phung HT, Nguyen CV, Mai NT, Vu HTN, Pham KH, Tran GL. Phung HT, et al. Technol Cancer Res Treat. 2022 Jan-Dec;21:15330338221080941. doi: 10.1177/15330338221080941. Technol Cancer Res Treat. 2022. PMID: 35379053 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal